Pfizer Japan and Takeda Launch "Enbrel® Subcutaneous Injection 50mg Pen 1.0mL", New Method of Administration for Rheumatoid Arthritis Treatment Enbrel®
Pfizer Japan Inc. (Head office: Shibuya-ku, Tokyo; "Pfizer") and Takeda Pharmaceutical Company Limited (Head office: Chuo-ku, Osaka; "Takeda") jointly announced that both parties launch on June 10, 2013 Enbrel Subcutaneous Injection 50mg Pen 1.0mL, a new method of administration for the rheumatoid arthritis medicine Enbrel (etanercept) which is being co-promoted by both parties.
The drug obtained regulatory approval from the Ministry of Health, Labour and Welfare on March 22, 2013 and its NHI (National Health Insurance) price for reimbursement was list on May 31, 2013.
Enbrel Subcutaneous Injection 50mg Pen 1.0mL is an autoinjector pen pre-filled preparation with the same composition as the conventional Enbrel Subcutaneous Injection 50mg Syringe 1.0mL, and it is expected to offer the following benefits for patient population.
- Easy administration by clicking on a button on the top of the pen
- Concealing the injection needle in the pen body to alleviate the discomfort of patients who prefer not to see the needle during injection
- Design that reduces the risk of accidental pricking -- and infection -- following administration.
- Easier to use than its syringe equivalent, possibly reducing patients' burden and the time and effort spent by medical institutions training patients in its use.
"We are delighted to be able to provide an easy-to-use treatment option to rheumatoid arthritis patients with pain and swelling in their joints," said Mark Swindell, Regional President Asia-Pacific, Specialty Care, Japan Business Unit Head. "Enbrel is the biological preparation that has the longest history of usage in rheumatoid arthritis treatment in the world. We hope that the introduction of autoinjector pen will be an opportunity to provide a better treatment option to patients who have been reluctant to self-administer."
"Conventional vial form of Enbrel was launched in March 2005 in Japan, followed by syringe preparations in June 2008, we are now able to start providing pen preparations which offer better convenience for patients," said Masato Iwasaki, Ph.D., Senior Vice President, Pharmaceutical Marketing Division of Takeda.
"Since rheumatoid arthritis requires long-term treatment, it is important to continue treatment while mitigating mental and physical burdens on patients. The 50mg autoinjector pen enables quick and safe administration with one click, making self-injection easier. We are excited to offer this new treatment option to an even greater number of rheumatoid patients."